Clinical outcomes in children and adolescents with recurrent or progressing high-grade glioma are poor. The median overall survival is approximately five months Pediatric high-grade gliomas are immunologically silent or […]
On June 10, the Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) in the first-line setting as monotherapy for patients whose tumors express PD-L1 or in […]
DNA detection of persistent oral human papillomavirus (HPV) may be associated with recurrence of squamous cell carcinoma of the head and neck positive for HPV (HNSCC). […]